Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.66 |
| ▸ | LPL | P06858 | 11/20 | 0.66 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24377155 | 1.00 | LIPG (0.66) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377025 | 0.97 | LIPG (0.65) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377083 | 0.93 | LIPG (0.67) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377030 | 0.93 | LIPG (0.71) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377090 | 0.92 | LIPG (0.64) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377074 | 0.91 | LIPG (0.63) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL19119784 | 0.91 | LIPG (0.68) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377386 | 0.91 | LIPG (0.67) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377075 | 0.91 | LIPG (0.62) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL24377051 | 0.90 | LIPG (0.79) | LIPGLPLDGAT1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023085606-A1 | ORGANIC ELECTRIC ELEMENT COMPRISING COMPOUND FOR ORGANIC ELECTRIC ELEMENT, AND ELECTRONIC DEVICE THEREOF | 덕산네오룩스 주식회사 | 2023-05-19 | — | — | WO | disclosed |
| US-20220131082-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220131082-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | NFE2L2, OR51E2, ETV6 | LIPG 1623/4885LPL 1617/4885DGAT1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.